Topotecan, Ara-C, Cisplatin and Prednisolone (TOPOSHAP) for Patients with Refractory and Relapsing Lymphomas: Results of a Phase I Trial

Publisher： Karger

E-ISSN： 1421-9662|112|3|121-125

ISSN： 0001-5792

Source： Acta Haematologica, Vol.112, Iss.3, 2004-09, pp. : 121-125

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Topotecan, Ara-C, Cisplatin and Prednisolone (Toposhap) for Patients with Refractory and Relapsing Lymphomas: Results of a Phase II Trial

By  

Acta Haematologica, Vol. 116, Iss. 4, 2006-11 ,pp. : 275-278

Karger

Access to resources Recommend Favorite

A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 61, Iss. 4, 2001-11 ,pp. : 265-270

Karger

Access to resources Recommend Favorite

Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and Vinorelbine

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 35-41

Karger

Access to resources Recommend Favorite

A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 25-29

Karger

Access to resources Recommend Favorite

Mitomycin C, 5-Fluorouracil, Leucovorin, and Oxaliplatin as a Salvage Therapy for Patients with Cisplatin-Resistant Advanced Gastric Cancer: A Phase I Dose Escalation Trial

By  

Oncology Research and Treatment, Vol. 30, Iss. 1-2, 2007-01 ,pp. : 29-34

Karger

Access to resources Recommend Favorite